0000899243-20-002644.txt : 20200203 0000899243-20-002644.hdr.sgml : 20200203 20200203205538 ACCESSION NUMBER: 0000899243-20-002644 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200201 FILED AS OF DATE: 20200203 DATE AS OF CHANGE: 20200203 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Fairey William CENTRAL INDEX KEY: 0001727275 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37609 FILM NUMBER: 20570382 MAIL ADDRESS: STREET 1: C/O CHEMOCENTRYX, INC. STREET 2: 850 MAUDE AVE. CITY: MOUNTAIN VIEW STATE: CA ZIP: 94043 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MyoKardia Inc CENTRAL INDEX KEY: 0001552451 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 455500552 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 333 ALLERTON AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-741-0900 MAIL ADDRESS: STREET 1: 333 ALLERTON AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-02-01 0 0001552451 MyoKardia Inc MYOK 0001727275 Fairey William C/O MYOKARDIA, INC. 333 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 0 1 0 0 See Remarks Common Stock 2020-02-01 4 M 0 8125 A 8125 D Common Stock 2020-02-01 4 S 0 2899 68.04 D 5226 D Restricted Stock Units 2020-02-01 4 M 0 8125 0.00 D Common Stock 8125 24375 D Restricted Stock Units ("RSUs") convert into common stock on a one-for-one basis. Represents the number of shares of Issuer's Common Stock sold to cover the Reporting Person's withholding taxes in connection with the vesting of 8,125 shares of Common Stock underlying the Reporting Person's RSUs. Each RSU represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in four annual installments after February 1, 2019, subject to the Reporting Person's continuous service to the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. Executive Vice President, Chief Commercial Officer /s/ Cynthia Ladd, as Attorney-in-Fact 2020-02-03